New Fibromyalgia Treatments in 2026: Tonmya, Stanza and What Patients Should Know
For years, people with fibromyalgia have had a limited number of treatment options. Two developments—a newly approved prescription medicine and an FDA-cleared digital therapy—are giving patients and clinicians more tools to consider.
Living with fibromyalgia often means managing much more than widespread pain. Fatigue, unrefreshing sleep, brain fog and reduced physical function can affect work, relationships and ordinary daily activities. Treatment can also involve trial and error because no single approach works for everyone.
The fibromyalgia treatment landscape has changed since this article was first published in February 2025. Tonmya, which was still awaiting a decision at that time, is now FDA-approved and commercially available in the United States. Stanza remains an FDA-cleared prescription digital therapy for fibromyalgia symptoms.
Tonmya: A New Bedtime Prescription for Adults With Fibromyalgia
Tonmya is the brand name for cyclobenzaprine hydrochloride sublingual tablets. “Sublingual” means the tablet is placed under the tongue. It is taken at bedtime and is described by its manufacturer as a non-opioid analgesic.
The FDA approved Tonmya for the treatment of fibromyalgia in adults on August 15, 2025. It was the first new prescription medicine approved for fibromyalgia in more than 15 years. Its approval incorporated results from two randomized, double-blind, placebo-controlled Phase 3 trials involving nearly 1,000 participants.
In those studies, people receiving Tonmya experienced a statistically significant reduction in daily pain scores compared with those receiving placebo after 14 weeks. That does not mean everyone improved or that the medicine eliminates fibromyalgia; it means the average trial results met the studies’ primary measure.
What patients should know about side effects
Reported common adverse events included numbness, tingling, discomfort or pain in the mouth; unusual taste; drowsiness; fatigue; dry mouth; and canker sores. A clinician and pharmacist can explain the complete prescribing information, medication interactions and whether Tonmya may be appropriate for you.
Stanza: Behavioral Therapy Delivered Through a Smartphone
Stanza is not a medication. It is a prescription digital therapeutic that received FDA De Novo authorization in May 2023 for treating fibromyalgia symptoms in adults.
According to the FDA authorization, Stanza delivers Acceptance and Commitment Therapy, a form of cognitive behavioral therapy. The self-guided program is accessed through a smartphone and is designed to teach skills for responding to symptoms and setbacks.
This distinction matters: the FDA approved Tonmya as a drug and authorized/cleared Stanza as a Class II medical device. Both are regulated treatment options, but they work differently and are evaluated through different regulatory pathways.
What does the research show?
Swing Therapeutics reports that randomized trials found improvements in fibromyalgia-related well-being and symptom measures. Follow-up findings reported in 2025 suggested that improvements observed after the program were maintained for some study participants at 12 months. Individual results may vary, and access requires a prescription.
Insurance coverage and availability can differ by plan and location. Patients interested in Stanza should ask their clinician and insurer about current access rather than assuming it is automatically covered.
Tonmya and Stanza Are Not the Same Kind of Treatment
| Feature | Tonmya | Stanza |
|---|---|---|
| Type | Prescription medicine | Prescription digital medical device |
| Regulatory status | FDA-approved in August 2025 | FDA De Novo authorized in May 2023 |
| How it is used | Sublingual tablet taken at bedtime as prescribed | Self-guided behavioral therapy delivered through a smartphone |
| Main approach | Non-opioid pharmacologic treatment | Acceptance and Commitment Therapy-based behavioral treatment |
| Access | Prescription; insurance and pharmacy coverage vary | Prescription; program availability and coverage vary |
Why Comprehensive Fibromyalgia Care Still Matters
A new medicine or digital tool does not erase the need for individualized care. Fibromyalgia is complex, and many treatment plans combine several approaches.
Medication review
A clinician may consider approved medicines, existing prescriptions, side effects and interactions.
Sleep support
Sleep problems are common and may need assessment beyond simply trying to spend more time in bed.
Gentle movement
Activity may be introduced gradually and adjusted to avoid the boom-and-bust cycle that can follow overexertion.
Behavioral support
Approaches such as CBT or ACT may help people respond differently to pain, stress and setbacks.
Pacing
Balancing activity and rest can help patients use their available energy more intentionally.
Related conditions
Migraine, depression, anxiety, sleep disorders and other conditions may require their own evaluation.
Questions to Ask Your Doctor
- Could Tonmya be appropriate given my symptoms and current medications?
- What side effects or drug interactions should I understand?
- Would a digital behavioral therapy such as Stanza fit my treatment plan?
- Does my insurance cover either option, and what might I pay?
- How will we measure whether a treatment is helping?
- How long should I try it before we reassess?
- What non-drug approaches should I use alongside treatment?
Frequently Asked Questions
What is the newest FDA-approved fibromyalgia medicine?
Tonmya (cyclobenzaprine hydrochloride sublingual tablets) was FDA-approved on August 15, 2025 for treating fibromyalgia in adults. It was commercially launched in the United States in November 2025.
Is Tonmya the same as regular cyclobenzaprine?
Tonmya contains cyclobenzaprine hydrochloride but uses a specific sublingual formulation and dosing instructions approved for fibromyalgia. Do not substitute or alter medication on your own; ask a prescriber or pharmacist.
Is Tonmya an opioid?
No. Tonmya is described as a non-opioid prescription analgesic.
What is Stanza for fibromyalgia?
Stanza is an FDA-cleared prescription digital therapeutic for adults with fibromyalgia symptoms. It delivers Acceptance and Commitment Therapy through a smartphone-based program.
Is Stanza a medication?
No. Stanza is regulated as a prescription digital medical device, not a drug.
Will insurance pay for Tonmya or Stanza?
Coverage varies by insurer, plan, location and clinical requirements. Contact your insurer and the prescribing provider for current information.
Do these treatments cure fibromyalgia?
No. Neither treatment is considered a cure. They are options intended to help manage fibromyalgia or its symptoms, and individual results vary.
What These Advancements Mean for Patients
The most encouraging part of these developments is not the promise of a miracle. It is the expansion of choice. One option is a newly approved bedtime medication; the other brings evidence-based behavioral therapy to a smartphone. They may be used differently and will not suit everyone, but they give patients and clinicians more to discuss than they had several years ago.
If you are interested in either option, bring the names to your next appointment and ask direct questions about risks, expected benefits, cost and how success would be measured. You deserve a treatment conversation that takes your symptoms seriously.
Have you discussed either Tonmya or prescription digital therapy with your healthcare provider? Share what questions you still have below.
